If im not here, Im at: ⬇️ 📸 IG: https://t.co/ZxC9PjhCpy 🦋Bsky: https://t.co/WVaAZaw6BY 🧵Threads:

Prof. Sandra Navarra outlines the 5 management pillars for implementing the Treat-to-Target (T2T) strategy in #SLE: early adoption, evidence-based treatment choices, shared decision-making, non-pharmacologic management, and digital tools for monitoring. #LupusAcademy2025

Dr Sandra Navarra highlights some of the SLE patients' unmet needs and the importance of patient involvement. A great example of this involvement is the Patient Charter, in which our Chair, @Jeanette_Lupus, was involved. #LupusAcademy2025

FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts.

✍️ Abstract submission for the EULAR 2026 Congress is NOW OPEN! Present your ground-breaking research at the EULAR Congress in London, UK. 🔗 Submit your abstract before 15 January 2026 here: https://t.co/dsViPJRrGc #EULAR2026

They’re fresh. They’re brilliant. They’re finally here! Over 3,100 #ACR25 abstracts are now available for your viewing pleasure. P.S. Late-breaking abstracts will be published in early October. 👀 SEE THEM ALL → https://t.co/o0fpZCHZLC

Progress in care doesn’t happen by accident. It starts with bold ideas shared openly by those who dare to think beyond the expected, & ACR Convergence scientific sessions are the birthplace of #rheum breakthroughs! Got a session suggestion for #ACR26? Now’s your chance to speak

Great to see some @APLAR_org region representatives! Looking forward to see your tweets! #ACR25

signing off for now. see yall in IG, blue sky and threads.

IL-17is demonstrate efficacy in SpA tx Comparable with TNFis & JAKis in terms of achieving ASAS40 response rates IL-17is are generally well-tolerated w/⬇️TB risk (very important tx consideration esp in Asia) But watch out for candidal infx, IBD exacerbation @RheumNow #APLAR25

A wonderful congress with really fruitful sessions, talented and outstanding physicians and scientists and good friends. #APLAR2025 #PediatricRheumatologists #ChangGungMemorialHospital

PsO/PsA patients have an ⬆��� CV risk brought about by traditional and CV risk factors. Do you perform regular CV risk screening in your patients? @RheumNow #APLAR25

It’s a wrap! Thank you for a wonderful #APLAR25 conference 😀 ✅ New learnings ✅ Reported for @RheumNow with @AurelieRheumo ✅ Met new friends F2F @ori_114 ✅ Connected w/🇵🇭 & international rheums from @APLAR_org @rheumarhyme

@rheumarhyme @RHEUMarampa @theactiverheum Lovely meeting @RHEUMarampa in person 🥰 See you all next time ✨

To learn from the experts. To work with an outstanding team. To connect with pediatric rheumatologists from around the world. It’s truly incredible! 😊 Many thanks to those who has dedicated themselves to improving care for children with rheumatic diseases #APLAR25 #PaedPower

Honored to contribute 3 abstracts at #APLAR2025: 📊 From the #Saudi_Arthritis_Registry 📖 2 on the development of Gulf Guidelines for SLE management @Dr_Samaralemadi Proud to be part of efforts shaping rheumatology practice in our region. 🌍🧑‍⚕️ #Rheumatology #SLE #APLAR

President Dr Paulo Lorenzo closes the 27th APLAR Congress with his message to advance rheumatology improving and inspiring lives thru unity in diversity 🌐 #APLAR2025 #APLAR25

GCs have potent anti-inflammatory effects but it’s long term complications can be catastrophic. In SLE pts, it shows a 3-fold increased risk of organ damage for each addtl 1mg of Pred/day. 📌Aim for short duration of use with lowest effective dose @RheumNow #APLAR25

Prof. Masataka Kuwana 🇯🇵 highlights: PH with ILD in SARDs = severe complication with high morbidity & mortality 🚨. 🌸 Inhaled treprostinil offers hope for better outcomes 💊 Sildenafil safe, well-tolerated, option if treprostinil unavailable #APLAR25 #Rheumatology #PH #ILD

From 📍🇺🇸Washington to 📍🇯🇵Fukuoka (@ 🇵🇭 Booth) @theactiverheum #FOAMed #APLAR25